Responses of CLL cells to purine analogs with cyclophosphamide ab 23.9 € als Taschenbuch: Drug-induced apoptosis of leukemic cells. Aus dem Bereich: Bücher, Wissenschaft, Biologie,
Responses of CLL cells to purine analogs with cyclophosphamide ab 23.9 EURO Drug-induced apoptosis of leukemic cells
Our findings demonstrate the need of ex vivo chronic lymphocytic leukemia cell (CLL) treatment before the application of drugs to select the most efficient manner of the patient s therapy. The obtained results confirm the link between the outcomes of the research done under ex vivo and in vivo conditions and underline the usefulness of ex vivo studies in the individual choice of CLL treatment. Our observations provide a base for further studies on the relationship between the in vivo clinical responses of patients and ex vivo pro-apoptotic activity, and the cytotoxicity of drugs against leukemic cells. Their validation by a study comprising a much larger group of patients is needed.
Coagulation disorders and abnormal platelet activation are frequent findings in hematological malignancies. A hypercoagulable state is induced by malignant cells interacting directly with haemostatic system and activating the coagulation cascade. This is descriptive, prospective analytical case- control study done in Radiation & Isotopes Center Khartoum (RICK) to determine the haemostatic abnormalities and vascular damage of hematological malignancies among the major Sudanese patients.Hemostasis studies shown that, there were decreased level of fibrinogenand antithrombin III, vWf and PAI-1 were significantly elevated in ALL and in AML patients. significantly low platelet counts in AML, CLL and increased in CML and CGL ( CML ph positive) in related to control group. D-dimers was positive in 79 % of patients.platelet aggregation in response to ADP, Collagen, and Epinephrine agonists was decreased in ALL, AML and MM, and in variable in CML and NHL, and increased in CLL and HL.Markers of coagulation and platelet defect was clearly observed in hematological malignancies patients, also indication of fibrinolysis and endothelial activation were confirmed
Flow cytometer became one of the most pivotal and definitive techniques in the diagnosis and classification of mature B cell neoplasm (MBCN). Since flow cytometer exploits the laser and photomultiplier technology for reliable high quality result with extremely high sensitivity and specificity, we used these important specifications in this project to study the properties of B cells in the adult patients whose have initial diagnosis of (MBCN). This book discussed the diversity of the flow cytometer parameters (such as the percentage of positive cells, the mean fluorescence intensity and the positive peak width) which showed a remarkable role in the diagnosis of MBCN and in differentiation between CLL and NHL. The worth of the idea of this diversity of the parameters exhibited in the minimization of the markers number following into the minimization of panel cost without affecting the result. Also, using of CD20 & CD19 with their flow cytometric parameters and without the other scoring markers showed a significant role in differentiation between CLL and NHL. These ideas are appropriate for the used in laboratories of limited resources.
Chronic lymphocytic leukemia is the most common leukemia affecting mainly elderly individuals and follows an extremely variable course, with survival ranging from months to decades. Several characteristics of CLL facilitate basic and translational research including the high population prevalence, the easily obtainable malignant cells through venous phlebotomy, the asymptomatic phase in most patients that allows for longitudinal evaluation, and the relatively long disease-specific survival. Consensus guidelines for treatment of patients with CLL have been proposed by the ESMO Clinical Practice Guidelines, and recently recommended that the current use of prognostic tools for patients with newly diagnosed CLL should include staging (Rai or Binet), lymphocyte doubling time (LDT), Beta-2 microglobulin (beta2M), CD38 and ZAP-70 markers, CLL-relevant fluorescence in situ hybridization (FISH) panel, and, if available, IgVH gene mutation status.
Leukaemia is commonly known as blood cancer with fatal characteristics. The age standardize rate of cancer in India is 60 to 90%. Epidemiology played an imperative role to understand the causes of diseases and its geographical prevalence which provides the opportunity to draft the policy and treatment strategies. In this book, an attempt is made to identify an epidemiological characteristic of leukemia patients of Gujarat state. This is the endeavor to describe the age-specific occurrence, deviation of hematological and biochemical parameter and genetic mutation of four main types of leukaemia (Chronic myeloid leukaemia CML, Chronic lymphoid leukaemia, CLL, Acute lymphoid leukaemia, ALL and Acute myeloid leukaemia, AML).
Chronic lymphocytic leukemia (CLL) is the most common hematological malignancy in western countries. It is characterized by the accumulation of monoclonal CD5+ B-lymphocytes in blood, bone marrow, and lymphoid organs, due to an imbalance between proliferation and cell death. It is a complex disease that remains misunderstood. This book, therefore describes globally this very common but extremely complex type of leukemia. Throughout this book the principal biological hallmarks of B-cells are compared with the principal features of CLL-leukemic B-cells. Additionally the current CLL epidemiology is indicated and the most common methods of diagnosis are discussed. Moreover, the principal prognostic factors of CLL are described, passing from a medical point of view to a biological description. The major characteristics conferring apoptotic avoidance of CLL cells and proliferation factors are detailed, such as the principal models for its in vitro and in vivo study. Finally, the leading conventional treatments and new therapeutic strategies against CLL are listed with their principal biological targets.
Chronic lymphocytic leukemia (CLL) is the most common leukemia in the Western world. CLL has a highly varied clinical course. While advances in CLL therapy are noted, many patients still succumb to this illness. Like most progress in medicine, solid advances in the diagnosis, prognosis and treatment of CLL are rooted in an in-depth understanding of the basic and translational biology of CLL. In this book, CLL experts have contributed state-of-the-art summaries of various important aspects of CLL biology and have discussed the translational implication of such findings. This book, which is directed at physicians and researchers alike, aims to educate broadly and deeply. Intentionally, the many aspects and nuances of CLL clinical care that can only really be appreciated through direct patient care are not covered here, but instead, the book presents basic aspects of CLL that underlie many of the contemporary decisions that are made in CLL research and clinical settings.We hope that this book will critically inform the community and stimulate interest in CLL, which will ultimately translate into better CLL research, prognostication and therapy, with the end goal of providing a better outlook for patients afflicted with this common leukemia.